IGC Pharma, Inc. (IGC) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US45408X3089

Price
0.18 USD
Market cap
20.54 m USD
P/E (2026)
–
P/S (2026)
17.32
Dividend yield
0.00 %
Net margin
-552.11 %
Return on equity (ROE)
-106.98 %
Return on assets (ROA)
-71.29 %

IGC Pharma, Inc. financials

Fiscal year20252026
Revenue1.27 m USD1.19 m USD
Gross profit619,000.00 USD352,000.00 USD
Operating income-7.45 m USD-10.20 m USD
EBIT-7.12 m USD–
Net income-7.12 m USD-6.55 m USD
Diluted EPS – continuing operations-0.09 USD–

Full history since 2006, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About IGC Pharma, Inc.

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.